Hemgenix has long been presented ‘conditional authorisation’. Because of this the eu Medicines Agency made the decision that the main advantages of Hemgenix are higher than its dangers, but the company must present more evidence following authorisation.a panel of 3 of medical professionals with abilities in diagnosing and managing people with h